A detailed analysis of the Global Canine Atopic Dermatitis Treatment Market 2023 is provided, including global, regional, and country-level market sizes, segmentation market growth, market share, competitive landscape, sales analysis, impact of domestic and global Canine Atopic Dermatitis Treatment Market players, value chain optimization, trade regulations, recent developments, strategic market growth analyses, product launches, expanding the area market, and technological advances.
The global canine Atopic Dermatitis treatment market size was USD 887.4 million in 2022 and is expected to reach USD 3374.75 million in 2032 growing at a CAGR of 16% during the forecast period. Popularity of atopic dermatitis in dogs, rising pet ownership, and pet owners are becoming more concerned about the health of their animals, are major factors driving market revenue growth.
Dogs frequently get the chronic skin condition known as canine atopic dermatitis, which is brought on by dust mites, pollen, and mould spores, among other environmental allergens. Its symptoms include ear infections, itchiness, skin irritation, and hair loss.
In the pharmaceutical and healthcare sectors, there is rapid change. As cell and gene therapies become increasingly available, patients are finding appropriate treatments for previously incurable diseases. Machine learning and artificial intelligence (AI) technologies are making it possible for more inventive, faster, and cheaper therapy development to take place. By utilizing data-driven projects, manufacturing, the supply chain, and the entire healthcare ecosystem can benefit. It is clear that consumer attitudes and behaviors are shifting, ranging from a greater use of technology and data sharing to a willingness to use tools to make prescriptions and treatment decisions. Pharma and healthcare markets are expected to grow in the next few years as a result of such factors.
In 2020, Elanco Animal Health announced the acquisition of Aratana Therapeutics, which is a veterinary biopharmaceutical company, for USD 245 million. The acquisition was aimed at expanding Elanco's product portfolio in the companion animal market and strengthening its presence in the global canine atopic dermatitis treatment market.
New Product Launches:
Elanco Animal Health: On 5 August 2015, Elanco Animal Health launched Osurnia, a new treatment for otitis externa in dogs. Otitis externa is a common condition in dogs, and it is characterized by inflammation of the external ear canal. Osurnia is an ear gel that provides relief from inflammation and pain associated with otitis externa in dogs.
We can also provide the customized data for separate regions like North America, United States, Canada, Mexico, Asia-Pacific, China, India, Japan, South Korea, Australia, Indonesia, Singapore, Rest of Asia-Pacific, Europe, Germany, France, UK, Italy, Spain, Russia, Rest of Europe, Central & South America, Brazil, Argentina, Rest of South America, Middle East & Africa, Saudi Arabia, Turkey, Rest of Middle East & Africa
About Reports and Data
Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target and analyze consumer behavior shifts across demographics, across industries and help client’s make a smarter business decision. We offer market intelligence studies ensuring relevant and fact-based research across a multiple industries including Healthcare, Technology, Chemicals, Power and Energy. We consistently update our research offerings to ensure our clients are aware about the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise.